ningetinib

Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) that targets multiple receptor tyrosine kinases implicated in tumor growth and resistance mechanisms. Its primary targets include c-Met (hepatocyte growth factor receptor), vascular endothelial growth factor receptor 2 (VEGFR2), Axl, Mer, RON, and Fms-like tyrosine kinase 3 (FLT3). By inhibiting these kinases, ningetinib disrupts signaling pathways essential for tumor cell proliferation, survival, angiogenesis, invasion, and metastasis. It has demonstrated antitumor activity in preclinical models of acute myeloid leukemia with FLT3 mutations as well as various solid tumors. Ningetinib is under clinical investigation primarily for non-small cell lung cancer (NSCLC), hepatocellular carcinoma (liver cancer), and renal cell carcinoma[1][2][3][4][6][8].

Other names

ningetinib-tosylateningetinib toluenesulfonate1394820-69-9